Title: Vedolizumab–steroid combination therapy improves long-term prognosis in patients with
ulcerative colitis
Version: 2 Date: 12 Apr 2025
Reviewer's report:
The authors present their findings regarding the concomitant administration of corticosteroids
at vedolizumab initiation and show increased clinical response and remission as well as longer
drug continuation. However, there are several limitations.
Introduction:
Overall, the English is poor and the manuscript could benefit from a native speaker
104-105. Data are not lacking; on the contrary, there have been numerous studies with larger
number of patients
Methods:
Please indicate your follow-up period. The primary endpoint was vdz continuation at which
time-point?
For how long did the +PSL group receive prednisolone?
What were the criteria to assign each patient to a group?
Results:
Table 1:
The non rPSL group includes an increased number of patients with endoMAYO=3. Although
in a non statistically significant level, it could influence the results
Data on prior biologics exposure should be included
Data regarding the steroid refractoriness of each group are important, could influence the results
and should be included.
Overall, the small number of the cohort, the already available data of larger cohorts that show
no benefit from the concomitant corticosteroids and the above-mentioned limitations can not
be overpassed.
Title: Vedolizumab–steroid combination therapy improves long-term prognosis in patients with
ulcerative colitis
Version: 2 Date: 12 Apr 2025
Reviewer's report:
The authors present their findings regarding the concomitant administration of corticosteroids
at vedolizumab initiation and show increased clinical response and remission as well as longer
drug continuation. However, there are several limitations.
Introduction:
Overall, the English is poor and the manuscript could benefit from a native speaker
104-105. Data are not lacking; on the contrary, there have been numerous studies with larger
number of patients
Methods:
Please indicate your follow-up period. The primary endpoint was vdz continuation at which
time-point?
For how long did the +PSL group receive prednisolone?
What were the criteria to assign each patient to a group?
Results:
Table 1:
The non rPSL group includes an increased number of patients with endoMAYO=3. Although
in a non statistically significant level, it could influence the results
Data on prior biologics exposure should be included
Data regarding the steroid refractoriness of each group are important, could influence the results
and should be included.
Overall, the small number of the cohort, the already available data of larger cohorts that show
no benefit from the concomitant corticosteroids and the above-mentioned limitations can not
be overpassed.
Please review this paper.
user
Title: Vedolizumab–steroid combination therapy improves long-term prognosis in patients with
ulcerative colitis
Version: 2 Date: 12 Apr 2025
Reviewer's report:
The authors present their findings regarding the concomitant administration of corticosteroids
at vedolizumab initiation and show increased clinical response and remission as well as longer
drug continuation. However, there are several limitations.
Introduction:
Overall, the English is poor and the manuscript could benefit from a native speaker
104-105. Data are not lacking; on the contrary, there have been numerous studies with larger
number of patients
Methods:
Please indicate your follow-up period. The primary endpoint was vdz continuation at which
time-point?
For how long did the +PSL group receive prednisolone?
What were the criteria to assign each patient to a group?
Results:
Table 1:
The non rPSL group includes an increased number of patients with endoMAYO=3. Although
in a non statistically significant level, it could influence the results
Data on prior biologics exposure should be included
Data regarding the steroid refractoriness of each group are important, could influence the results
and should be included.
Overall, the small number of the cohort, the already available data of larger cohorts that show
no benefit from the concomitant corticosteroids and the above-mentioned limitations can not
be overpassed.
assistant